Navigation Links
Dendreon Announces Election of Dr. David C. Stump to Board of Directors
Date:6/2/2010

SEATTLE, June 2 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that David C. Stump, M.D., has been elected to the Company's Board of Directors.  Dr. Stump is currently executive vice president of research and development for Human Genome Sciences, Inc. (Nasdaq: HGSI), where he has been a member of its management committee since 1999.

"We welcome Dave to Dendreon's Board of Directors.  With more than 20 years of experience in global drug development and clinical research, Dave is an ideal addition to our board, particularly as Dendreon initiates its ex-U.S. strategy and expands its clinical development program to develop new and innovative treatment options for cancer patients," said Richard B. Brewer, chairman of the Dendreon Board of Directors.  

Prior to joining Human Genome Sciences, Inc., Dr. Stump held positions of increasing responsibility over a decade at Genentech, Inc., including vice president of clinical research.  He was named a Genentech Fellow in 1996 for leadership of its cardiovascular drug development activities.  In his later roles he was also responsible for pulmonary, oncology, and neuroendocrine clinical development programs.  He served as a member of the research review, clinical review, and product development committees which were responsible for oversight of all internal and external research and development opportunities.  Prior to Genentech, Dr. Stump served as associate professor of medicine and biochemistry at the University of Vermon
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 The maker community ... types of inventions. They focus on learning practical skills ... community gravitate toward bringing their ideas to life via ... Movement, works on making projects using biology. Glowing Plant ... plants to make them glow with bioluminescence genes, and ...
(Date:5/23/2013)... SAN MARINO, Calif. , May 23, 2013 ... announces today a strategic alliance with DAK Renewable ... increase the corn oil yield. VG Energy is ... Inc. (OTC Pink: VGLS). VG Energy,s ... pathways to increase the oil yield in plants, ...
(Date:5/23/2013)... Virobay, Inc. today announced that their development ... important milestone, as Virobay has now initiated a Phase ... S inhibitor.   The first Phase 1 ... designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics ... "The initiation of this Phase 1 trial with ...
(Date:5/23/2013)... May 23, 2013 On April 19th ... to supermarkets to search for the growing antibiotic resistant ... Results from a year long study were released late ... foods, specifically meats, over previous years. For those suffering ... growth of antibiotic resistant bacteria in food, may eventually ...
Breaking Biology Technology:Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2
... my life, but I am an academic researcher at heart. ... software company, so I wear three sets of interchangeable glasses ... in the belly of the beast, I know too well ... out the door, but I am first and foremost a ...
... - Calling the destruction of human embryos a line that ... bill that would have overturned his ban on new federal funding ... in the House of Representatives. , ,"It crosses a moral boundary ... Bush said in announcing the veto, the first of his presidency. ...
... A shland, Wis. - Determining how technology can ... honest assessment of what doesn't make sense. , ... institution in its backyard, it simply won't become the nation's ... incentives are thrown on the table. With 40-plus states, including ...
Cached Biology Technology:Judging educational software 2Judging educational software 3Judging educational software 4Bush vetoes stem cell research bill 2Bush vetoes stem cell research bill 3Technology in the Northwoods 2Technology in the Northwoods 3
(Date:5/23/2013)... Neuron , the team reveal the interplay of ... funded by the Wellcome Trust and BBSRC. , ... we improve our perceptual abilities. While these changes can ... also affect the fidelity of that response. ... explains: "When you communicate with others, you can make ...
(Date:5/22/2013)... fuel cell powered buses, including a team from ... degradation processes and bus membrane durability. , The ... stressors in the operating cycle of the bus ... the study, led by SFU graduate student Natalia ... at Burnaby-based Ballard Power Systems and funded by ...
(Date:5/22/2013)... A new, streamlined approach to genetic engineering drastically ... new genes into bacteria, the workhorses of biotechnology, ... ACS Synthetic Biology , the method paves the ... for drug development, environmental cleanup and other activities. ... or integrating, a piece of the genetic material ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2
... Animals and plants may not be able to evolve their way ... UC Davis study of a tiny seashore animal. The work was ... Royal Society B . The tide pool copepod Tigriopus ... in a unique lab study, the animals showed little ability to ...
... PHILADELPHIA Electrical engineers have long been toying ... be directly integrated into electronic circuits. University of Pennsylvania ... so they can operate in open-air environments, and, more ... measure the electrical properties of these and similar devices. ...
... of scientists, with Spanish participation, has shed light on ... acts for the first time in the moustached tamarin ... their infants without help from male group members, commit ... their offspring if they are stressed and in competition ...
Cached Biology News:Can evolution outpace climate change? 2Penn researchers develop biological circuit components, new microscope technique for measuring them 2Penn researchers develop biological circuit components, new microscope technique for measuring them 3Competition between females leads to infanticide in some primates 2
... for covering tissue sections and cell preparations immunohistochemically ... insoluble end products. UltraMount Plus can ... or AEC that require an aqueous mounting medium, ... No heating is required prior to use. This ...
... to JAK2 (phospho Y1007) ( Abpromise ... Antigen: Synthesized phosphopeptide ... phosphorylation site of tyrosine 1007 (K-E-Y ... Gene ID: 3717 ...
Rabbit polyclonal to JNK1 (phospho T183 + Y185) ( Abpromise for all tested applications). entrezGeneID: 5599 SwissProtID: P45983...
... Abpromise for all tested applications). ... to KLH derived from within residues 400 ... acid sequence is proprietary)(Peptide available as ... ID: 55693 Swiss ...
Biology Products: